Live price temporarily unavailable.
FibroBiologics (FBLG) is a Health Care company. Latest news and coverage below.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$4.47M | −$8.89M | −$13.7M | −$16.6M |
| Net income | −$5.12M | −$16.5M | −$11.2M | −$18.6M |
| EPS (diluted) | −$3.60 | −$13.60 | −$6.80 | −$8.40 |
| Balance sheet | ||||
| Cash and equivalents | $2.27M | $9.16M | $14.0M | $4.89M |
| Total assets | $4.82M | $11.8M | $16.4M | $9.62M |
| Total liabilities | $8.82M | $10.6M | $13.7M | $3.46M |
| Shareholders' equity | −$4.00M | $1.25M | $2.73M | $6.16M |
| Cash flow | ||||
| Operating cash flow | −$4.07M | −$6.40M | −$11.9M | −$16.4M |
| Capital expenditure | — | $495.0K | $184.0K | $262.0K |
| Free cash flow | — | −$6.90M | −$12.1M | −$16.7M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$3.35M | −$3.71M | −$4.53M | −$4.49M | −$5.04M | −$2.59M | −$5.07M | −$4.03M |
| Net income | −$500.0K | −$3.10M | −$4.97M | −$4.66M | −$5.78M | −$3.24M | −$5.00M | −$4.12M |
| EPS (diluted) | −$0.20 | −$1.80 | −$54.20 | −$2.41 | −$2.60 | $50.81 | −$26.60 | −$0.66 |
| Balance sheet | ||||||||
| Cash and equivalents | $7.83M | $14.0M | $8.67M | $8.85M | $4.87M | $4.89M | $1.48M | $3.52M |
| Total assets | $10.5M | $16.4M | $11.4M | $13.9M | $8.74M | $9.62M | $5.94M | $7.93M |
| Total liabilities | $7.73M | $13.7M | $9.08M | $13.0M | $8.62M | $3.46M | $3.34M | $3.29M |
| Shareholders' equity | $2.74M | $2.73M | $2.35M | $860.0K | $125.0K | $6.16M | $2.60M | $4.64M |
| Cash flow | ||||||||
| Operating cash flow | −$2.61M | −$3.07M | −$5.28M | −$3.98M | −$3.97M | −$3.16M | −$4.36M | −$3.29M |
| Capital expenditure | $11.0K | $99.0K | $43.0K | $213.0K | $6.00K | $0 | $0 | $0 |
| Free cash flow | −$2.62M | −$3.17M | −$5.32M | −$4.20M | −$3.98M | −$3.16M | −$4.36M | −$3.29M |
From FibroBiologics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning FibroBiologics in our feed yet.